Originally launched in 2014 and updated through 2019, The New Antifungal Toolkit is an Internet CME curriculum that provides current information about newer FDA-approved agents/formulations for the management of invasive fungal infections (IFIs) and evaluates their role in strategies to optimize antifungal therapy. In the 2019 updates, we provide a review of SUBA-itraconazole, updates on endemic mycoses, as well as updates to the pharmacopeia section.
Release Date: 03/6/2019
Expiration Date: 03/5/2020
Estimated Time to Complete the Activity: 0.5 hr
Media: Interactive, text-based activity
Itraconazole is a mainstay of therapy for a range of fungal infections, including endemic mycoses. However, itraconazole has a challenging pharmacologic profile. Recently, SUBA-itraconazole received US FDA approval for management of endemic mycoses and aspergillosis. Clinicians need education about the enhanced pharmacology of this new formulation of itraconazole as well as expert guidance on how to use it, particularly in the setting of endemic mycoses.
Upon completing this activity, the participant should be better able to:
This activity is directed to infectious disease physicians, critical care physicians, hospitalists, surgeons, pathologists, hematologists/oncologists, pharmacists, and other healthcare providers responsible for the management of invasive mycoses.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine; Terranova Medica, LLC; and the Mycoses Study Group Education and Research Consortium (MSGERC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest or a commercial interest.
The following indicates the disclosure declaration information and the nature of those commercial relationships:
DIMITRIOS P. KONTOYIANNIS, MD, ScD, FACP, FIDSA, PhD Hon, FECMM, FAAM
CONSULTANT/ADVISORY BOARD:
Merck & Co, Inc., Mayne
RESEARCH SUPPORT:
Astellas
SPEAKERS BUREAU:
Gilead
RUSSELL E. LEWIS, PHARMD, FCCP, BCPS
RESEARCH SUPPORT:
Merck & Co, Inc.
CONSULTANT/ADVISORY BOARD:
Gilead Inc.
GEORGE R. THOMPSON, III, MD, FIDSA
RESEARCH SUPPORT:
Amplyx; Astellas; Cidara Therapeutics, Inc.; F2G
CONSULTANT/ADVISORY BOARD:
Amplyx; Astellas; Cidara Therapeutics, Inc.; F2G
The PIM planners and managers have nothing to disclose. The Terranova Medica, LLC planners/writers have nothing to disclose.
Peter G. Pappas, MD, FACP, of the MSGERC, has the following to disclose:
CONSULTANT:
Amplyx, Inc.; Cidara Therapeutics, Inc.; Scynexis; Vical
INDUSTRY-FUNDED RESEARCH/INVESTIGATOR:
Astellas; Cidara Therapeutics, Inc.; IMMY; T2 Biosystems; Scynexis; Vical
There are no fees for participating and receiving CME/CE credit for this activity. During the accreditation period, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps below:
Internet
To participate, you will need access to a computer (either MAC or PC), tablet, or smart phone, with a Chrome (version 22.0.1229.94 or greater) web browser, Firefox (version 3.6 or greater) web browser or an Internet Explorer (version 8.0 or greater) web browser, JavaScript enabled, connected to the Internet (high speed connection preferred).
Terranova Medica, LLC, and PIM are committed to protecting the privacy of those who choose to participate in activities on funguscme.org. This information below describes our security policies for safeguarding personal information as well as the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of personal information
Terranova Medica, LLC, and PIM do not transfer, sell, or share personal information with outside parties. We will not disclose the information unless required in a legal proceeding.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There is no charge for this activity.
Jointly provided by Postgraduate Institute for Medicine; Terranova Medica, LLC; and the Mycoses Study Group Education & Research Consortium.
This activity is supported by an independent educational grant from Mayne Pharma, Inc.
For further information, contact Tom Davis by telephone or fax (877-276-4523), or by email (tdavis@terranovamedica.com).
If you have any questions regarding the CME/CE certification for this activity, please contact Postgraduate Institute for Medicine at: inquiries@pimed.com or (303) 799-1930.
Copyright © 2019 PIM, MSGERC, and Terranova Medica.
